Prime Medicine
PRME | NASDAQ
$4.19
-$0.08 (-1.87%)
At close: Nov 16, 2026, 4:00 PM ET
$4.29
+$0.10 (+2.36%)
After-hours:
Nov 16, 2026, 7:46 PM ET
Prime Medicine Company Profile
Company profile explainedCompany Profile
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Allan Reine | Chief Executive Officer & Director |
| Ryan E. Brown | Chief Legal Officer |
| Svetlana Makhni | Chief Financial Officer |
| Andrew Anzalone | Co-Founder & Head of Platform |
| Ann L. Lee | Chief Technical Officer |
| David R. Liu | Co-Founder & Member of Scientific Advisory Board |
| Jeffrey D. Marrazzo | Executive Chair |
| Matthew J. Hawryluk | Chief Business Officer |
| Mohammed Asmal | Chief Medical Officer |
| Niamh Alix | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
| Jul 08, 2026 | 8-K | Current Report |
| Jun 08, 2026 | 4 | Filing |
| Jun 08, 2026 | 4 | Filing |
| Jun 08, 2026 | 4 | Filing |
| Jun 08, 2026 | 4 | Filing |
| Jun 08, 2026 | 4 | Filing |
| Jun 08, 2026 | 4 | Filing |
| Jun 08, 2026 | 4 | Filing |
Prime Medicine
| Country | United States |
| IPO Date | Oct 20, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 146 |
| CEO | Allan Reine |
Contact Details
60 First Street Cambridge,
Massachusetts 02141 United States
Stock Details
| Ticker Symbol | PRME |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001894562 |
| CUSIP Number | 74168J101 |
| ISIN Number | US74168J1016 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove PRME